Replies to post #80405 on Biotech Values

[DewDiligence]

ARYX: During a recent presentation, management attributed P&G's decision to drop ATI-7505 to P&G's decision to exit the drug business entirely. Do you think this is a plausible explanation or just spin from management?

The latter: spin. If a product candidate has bona fide commercial potential, large companies such as PG generally find a way to get some value for it.